Viridian data lift prospects for thyroid eye disease drug
BioPharma Dive
Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with chronic disease were viewed by analysts as much more competitive with Amgen s Tepezza.
pharminent
May 5, 2026 (Last updated: May 6, 2026)
BioPharma Dive
Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with chronic disease were viewed by analysts as much more competitive with Amgen s Tepezza.
